Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has accepted filing and review of the New Drug Application (NDA) for ridaforolimus, by Merck and Ariad Pharmaceuticals.
Subscribe to our email newsletter
Ridaforolimus is an investigational oral mTOR inhibitor to treat metastatic soft-tissue or bone sarcomas in patients who responded to chemotherapy.
The European Medicines Agency had earlier accepted the marketing authorization application for ridaforolimus.
Merck is known for the development and worldwide commercialization of ridaforolimus in oncology.